| ［1］ Wu J, Wu G, Lv L, et al. MicroRNA34a inhibits migration and invasion of colon cancer cells via targeting to Fra1［J］. Carcinogenesis, 2012, 33(3)： 519528.
［2］ Akao Y, Noguchi S, Iio A, et al. Dysregulation of microRNA34a expression causes drugresistance to 5FU in human colon cancer DLD1 cells［J］. Cancer Lett, 2011, 300(2)： 197204.
［3］ Lin PL, Wu DW, Huang CC, et al. MicroRNA21 promotes tumour malignancy via increased nuclear translocation of betacatenin and predicts poor outcome in APCmutated but not in APCwildtype colorectal cancer［J］. Carcinogenesis, 2014, 35(10)： 21752182.
［4］ Peacock O, Lee AC, Cameron F, et al. Inflammation and MiR21 pathways functionally interact to downregulate PDCD4 in colorectal cancer［J］. PLoS One, 2014, 9(10)： e110267.
［5］ Du M, Liu S, Gu D, et al. Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients［J］. Carcinogenesis, 2014, 35(12)： 27232730.
［6］ Oue N, Anami K, Schetter AJ, et al. High miR21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer［J］. Int J Cancer, 2014, 134(8)： 19261934.
［7］ Roy S, Yu Y, Padhye SB, et al. Difluorinatedcurcumin (CDF) restores PTEN expression in colon cancer cells by downregulating miR21［J］. PLoS One, 2013, 8(7)： e68543.
［8］ Hanahan D, Weinberg RA. Hallmarks of cancer： the next generation［J］. Cell, 2011, 144(5)： 646674.
［9］ Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR143/145 cluster by oncogenic Ras initiates a tumorpromoting feedforward pathway［J］. Genes Dev, 2010, 24(24)： 27542759.
［10］ Chivukula RR, Shi G, Acharya A, et al. An essential mesenchymal function for miR143/145 in intestinal epithelial regeneration［J］. Cell, 2014, 157(5)： 11041116.
［11］ Iliopoulos D. MicroRNA circuits regulate the cancerinflammation link［J］. Sci Signal, 2014, 7(318)： pe8.
［12］ Ma F, Xu S, Liu X, et al. The microRNA miR29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon［gamma］［J］. Nat Immunol, 2011, 12(9)： 861869.
［13］ Borralho PM, Simes AES, Gomes SE, et al. miR143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation［J］. PLoS One, 2011, 6(8)： e23787.
［14］ Yamakuchi M, Lotterman CD, Bao C, et al. P53induced microRNA107 inhibits HIF1 and tumor angiogenesis［J］. Proc Natl Acad Sci USA, 2010, 107(14)： 63346339.
［15］ Ma Y, BaoHan W, Lv X, et al. MicroRNA34a mediates the autocrine signaling of PAR2activating proteinase and its role in colonic cancer cell proliferation［J］. PLoS One, 2013, 8(8)： e72383.
［16］ Yin Y, Yan ZP, Lu NN, et al. Downregulation of miR145 associated with cancer progression and VEGF transcriptional activation by targeting NRAS and IRS1［J］. Biochim Biophys Acta, 2013, 1829(2)： 239247.
［17］ Shen WW, Zeng Z, Zhu WX, et al. MiR1423p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells［J］. J Mol Med, 2013, 91(8)： 9891000.
［18］ KoppersLalic D, Hogenboom MM, Middeldorp JM, et al. Virusmodified exosomes for targeted RNA delivery; a new approach in nanomedicine［J］. Adv Drug Deliv Rev, 2013, 65(3)： 348356.
［19］ Bryniarski K, Ptak W, Jayakumar A, et al. Antigenspecific, antibodycoated, exosomelike nanovesicles deliver suppressor Tcell microRNA150 to effector T cells to inhibit contact sensitivity［J］. J Allergy Clin Immunol, 2013, 132(1)： 170181.
［20］ Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins［J］. Nat Cell Biol, 2011, 13(4)： 423433.
［21］ Liu X, Suo R, Xiong SL, et al. HDL drug carriers for targeted therapy［J］. Clin Chimica Acta, 2013, 415： 94100. |
